<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>OBJECTIVE: Roux-en-Y gastric bypass (RYGB) ameliorates type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> in severely <z:mp ids='MP_0001261'>obese</z:mp> patients through mechanisms beyond just <z:hpo ids='HP_0001824'>weight loss</z:hpo>, and it may benefit less <z:mp ids='MP_0001261'>obese</z:mp> diabetic patients </plain></SENT>
<SENT sid="1" pm="."><plain>We determined the long-term impact of RYGB on patients with <z:mp ids='MP_0002055'>diabetes</z:mp> and only class I <z:hpo ids='HP_0001513'>obesity</z:hpo> </plain></SENT>
<SENT sid="2" pm="."><plain>RESEARCH DESIGN AND METHODS: Sixty-six consecutively selected diabetic patients with BMI 30-35 kg/m(2) underwent RYGB in a tertiary-care hospital and were prospectively studied for up to 6 years (median 5 years [range 1-6]), with 100% follow-up </plain></SENT>
<SENT sid="3" pm="."><plain>Main outcome measures were safety and the percentage of patients experiencing <z:mp ids='MP_0002055'>diabetes</z:mp> remission (HbA(1c) &lt;6.5% without <z:mp ids='MP_0002055'>diabetes</z:mp> medication) </plain></SENT>
<SENT sid="4" pm="."><plain>RESULTS: Participants had severe, longstanding <z:mp ids='MP_0002055'>diabetes</z:mp>, with disease duration 12.5 ± 7.4 years and HbA(1c) 9.7 ± 1.5%, despite insulin and/or oral <z:mp ids='MP_0002055'>diabetes</z:mp> medication usage in everyone </plain></SENT>
<SENT sid="5" pm="."><plain>For up to 6 years following RYGB, durable <z:mp ids='MP_0002055'>diabetes</z:mp> remission occurred in 88% of cases, with glycemic improvement in 11% </plain></SENT>
<SENT sid="6" pm="."><plain>Mean HbA(1c) fell from 9.7 ± 1.5 to 5.9 ± 0.1% (P &lt; 0.001), despite <z:mp ids='MP_0002055'>diabetes</z:mp> medication cessation in the majority </plain></SENT>
<SENT sid="7" pm="."><plain><z:hpo ids='HP_0001824'>Weight loss</z:hpo> failed to correlate with several measures of improved <z:chebi fb="105" ids="17234">glucose</z:chebi> homeostasis, consistent with weight-independent antidiabetes mechanisms of RYGB </plain></SENT>
<SENT sid="8" pm="."><plain>C-<z:chebi fb="7" ids="16670">peptide</z:chebi> responses to <z:chebi fb="105" ids="17234">glucose</z:chebi> increased substantially, suggesting improved β-cell function </plain></SENT>
<SENT sid="9" pm="."><plain>There was no mortality, major surgical morbidity, or excessive <z:hpo ids='HP_0001824'>weight loss</z:hpo> </plain></SENT>
<SENT sid="10" pm="."><plain><z:hpo ids='HP_0000822'>Hypertension</z:hpo> and <z:e sem="disease" ids="C0242339" disease_type="Disease or Syndrome" abbrv="">dyslipidemia</z:e> also improved, yielding 50-84% reductions in predicted 10-year <z:e sem="disease" ids="C0007222" disease_type="Disease or Syndrome" abbrv="CVD">cardiovascular disease</z:e> risks of fatal and nonfatal <z:e sem="disease" ids="C0010068" disease_type="Disease or Syndrome" abbrv="">coronary heart disease</z:e> and <z:hpo ids='HP_0001297'>stroke</z:hpo> </plain></SENT>
<SENT sid="11" pm="."><plain>CONCLUSIONS: This is the largest, longest-term study examining RYGB for diabetic patients without severe <z:hpo ids='HP_0001513'>obesity</z:hpo> </plain></SENT>
<SENT sid="12" pm="."><plain>RYGB safely and effectively ameliorated <z:mp ids='MP_0002055'>diabetes</z:mp> and associated comorbidities, reducing cardiovascular risk, in patients with a BMI of only 30-35 kg/m(2) </plain></SENT>
</text></document>